HC Wainwright Reaffirms Buy Rating for Lisata Therapeutics (NASDAQ:LSTA)

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $15.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 383.87% from the stock’s previous close.

Lisata Therapeutics Price Performance

LSTA stock opened at $3.10 on Wednesday. The firm has a market cap of $25.75 million, a PE ratio of -1.26 and a beta of 1.21. Lisata Therapeutics has a 12 month low of $1.96 and a 12 month high of $3.83. The firm has a 50 day simple moving average of $3.14 and a 200 day simple moving average of $3.11.

Lisata Therapeutics (NASDAQ:LSTA) last announced its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.14. During the same period last year, the business earned ($0.50) EPS. As a group, sell-side analysts expect that Lisata Therapeutics will post -2.97 earnings per share for the current year.

Institutional Trading of Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP raised its holdings in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,336 shares of the company’s stock after acquiring an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.21% of Lisata Therapeutics worth $60,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.